John
 
Matthew
 
Maris
M.D.
Email: 
Maris@email.chop.edu
Address: 
The Children's Hospital of Philadelphia Division of Oncology Colket Translational Research Building 3501 Civic Center Boulevard #3060 4399
215 590 5244
Affiliations
Expertise

Dr. Maris's research focuses on translational genomics and genetics of neuroblastoma.

Appointments
Assistant Professor of Pediatrics at University of Pennsylvania School of Medicine (1996 – 2004)
Associate Professor of Pediatrics at University of Pennsylvania School of Medicine (2004 – 2010)
Professor of Pediatrics at University of Pennsylvania School of Medicine (2010– present)
Education
M.D., Medicine, University of Pennsylvania (1989)
B.S., Biology, Wheeling College (1983)
Selected Publications
Kolb E Anders, Gorlick Richard, Reynolds C Patrick, Kang Min H, Carol Hernan, Lock Richard, Keir Stephen T, Maris John M, Billups Catherine A, Desjardins Christopher, Kurmasheva Raushan T, Houghton Peter J, Smith Malcolm A. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatric Blood & Cancer. Vol 60(8) . 2013 Aug:1325-32.
Wang Larry L, Suganuma Rie, Ikegaki Naohiko, Tang Xao, Naranjo Arlene, McGrady Patrick, London Wendy B, Hogarty Michael D, Gastier-Foster Julie M, Look A Thomas, Park Julie R, Maris John M, Cohn Susan L, Seeger Robert C, Shimada Hiroyuki. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group. Cancer. 2013 Jul.
Kreissman Susan G, Seeger Robert C, Matthay Katherine K, London Wendy B, Sposto Richard, Grupp Stephan A, Haas-Kogan Daphne A, Laquaglia Michael P, Yu Alice L, Diller Lisa, Buxton Allen, Park Julie R, Cohn Susan L, Maris John M, Reynolds C Patrick, Villablanca Judith G. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. The Lancet Oncology. 2013 Jul.
Maurer Barry J, Kang Min H, Villablanca Judith G, Janeba Jitka, Groshen Susan, Matthay Katherine K, Sondel Paul M, Maris John M, Jackson Hollie A, Goodarzian Fariba, Shimada Hiroyuki, Czarnecki Scarlett, Hasenauer Beth, Reynolds C Patrick, Marachelian Araz. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium. Pediatric Blood & Cancer. 2013 Jun.
Wood Andrew C, Maris John M, Gorlick Richard, Kolb E Anders, Keir Stephen T, Reynolds C Patrick, Kang Min H, Wu Jianrong, Kurmasheva Raushan T, Whiteman Kathleen, Houghton Peter J, Smith Malcolm A. Initial testing (stage 1) of the antibody-maytansinoid conjugate, IMGN901 (lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatric Blood & Cancer. 2013 Jun.
Mosse Yael P, Lim Megan S, Voss Stephan D, Wilner Keith, Ruffner Katherine, Laliberte Julie, Rolland Delphine, Balis Frank M, Maris John M, Weigel Brenda J, Ingle Ashish M, Ahern Charlotte, Adamson Peter C, Blaney Susan M. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. The Lancet Oncology. Vol 14(6) . 2013 May:472-80.
Yanik Gregory A, Parisi Marguerite T, Shulkin Barry L, Naranjo Arlene, Kreissman Susan G, London Wendy B, Villablanca Judith G, Maris John M, Park Julie R, Cohn Susan L, McGrady Patrick, Matthay Katherine K. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Journal of Nuclear Medicine. Vol 54(4) . 2013 Apr:541-8.
Suganuma Rie, Wang Larry L, Sano Hideki, Naranjo Arlene, London Wendy B, Seeger Robert C, Hogarty Michael D, Gastier-Foster Julie M, Look A Thomas, Park Julie R, Maris John M, Cohn Susan L, Amann Gabriele, Beiske Klaus, Cullinane Catherine J, d'Amore Emanuele S G, Gambini Claudio, Jarzembowski Jason A, Joshi Vijay V, Navarro Samuel, Peuchmaur Michel, Shimada Hiroyuki. Peripheral neuroblastic tumors with genotype-phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatric Blood & Cancer. Vol 60(3) . 2013 Mar:363-70.
Mayes Patrick A, Degenhardt Yan Y, Wood Andrew, Toporovskya Yana, Diskin Sharon J, Haglund Elizabeth, Moy Christopher, Wooster Richard, Maris John M. Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition. International Journal of Cancer. Vol 132(3) . 2013 Feb:E149-57.
Seif A E, Naranjo A, Baker D L, Bunin N J, Kletzel M, Kretschmar C S, Maris J M, McGrady P W, von Allmen D, Cohn S L, London W B, Park J R, Diller L R, Grupp S A. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplantation. 2013 Jan.